David Moller, M.D. has served as an Advisor to SarcoMed, USA since 2020. He has been instrumental in assisting the development of slides to explain the hypothesized Mechanism of Action in using DNase to treat pulmonary sarcoidosis and helped the SarcoMed clinical development team to generate its clinical study synopsis. Dr. Moller received his medical degree in 1979 from Tufts University; internal medicine residency at Albany Medical Center 1979-1982; Residential Fellow in Occupational Medicine, Allergy/Immunology at University of Cincinnati 1983-1985; Senior Staff Fellow at NHLBI, Pulmonary Branch 1985-1989. Thereafter, Dr. Moller from 1989-1997 served as Assistant Professor of Medicine at Johns Hopkins University School of Medicine; 1997-2020 served as Associate Professor of Medicine, then 2010-2019 served as Professor of Medicine, then 2019-present is Professor Emeritus all at Johns Hopkins University.
Dr. Moller has been a member of the Johns Hopkins University School of Medicine and a member of the faculty of the Multidisciplinary Training Program in Pulmonary Disease for over 30 years. His translational research has been focused on defining the immunologic basis of sarcoidosis and the determinants of remitting and chronic disease. His recent studies have focused on the role of pathogenic antigen-specific effector and regulatory T-cell and serum amyloid A in regulating granulomatous inflammation in sarcoidosis. Dr. Moller has a major interest in the clinical management and treatment of sarcoidosis. As a former Director of the Johns Hopkins Sarcoidosis Clinic for over 25 years, he has extensive expertise in all clinical aspects of this disease. He successfully partners in NIH-funded Multicenter Studies on the Epidemiology and Genetics of Sarcoidosis. More recently, he partnered on the multicenter GRADS Microbiome and Genomic study of Sarcoidosis and Alpha-1 Antitrypsin Deficiency and was co-chairman of the Protocol Committee. In March 2019, he was granted the title of Professor Emeritus, Medicine of Johns Hopkins University following his retirement. He has 49 Peer Reviewed Science publications, 17 invited reviews, 23 published case reports and 2 textbooks, “Sarcoidosis” 2012; “Clinical Handbook of Interstitial Lung Disease” 2018.